Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
Aug 26, 2023Apotex Corp. has expanded its oncology product portfolio with the launch of Bendamustine hydrochloride injection in the United States.
Bendamustine hydrochloride injection is an alkylating drug approved by FDA for treatment of patients with Chronic lymphocytic leukemia (CLL) and Indolent B-cell non-Hodgkin lymphoma (NHL). Please refer to the Prescribing Information for complete detail on indication, warnings and precautions.
Apotex’s Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL), New Drug Application No. 215033 contains the active drug ingredient (bendamustine hydrochloride) and is available in a multiple dose vial, ready-to-dilute solution, administered intravenously over 30 minutes for patients with CLL or 60 minutes for patients with NHL.
"We’re excited to launch this injection product, which provides an affordable, high-quality option for Americans undergoing cancer treatment," said Peter Hardwick, President, Apotex Corp.
About Apotex Corp.
Apotex Corp. is a US based company, headquartered in Weston, Florida. It and its global affiliates are leaders in generic pharmaceuticals and biosimilars and are committed to supplying patients with a broad portfolio of high-quality, affordable medicines covering all major therapeutic areas.
-30-
All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
jberman@apotex.com
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.